Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Study ID
- NCT06727838
- Phase
- PHASE1
- Status
- Completed
Conditions
- Diabetes
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- HRS-7535 tablets — DRUGHRS-7535 tablets.
- Metformin Hydrochloride Extended-release Tablets — DRUGMetformin Hydrochloride Extended-release Tablets.
- Metformin Hydrochloride Tablets — DRUGMetformin Hydrochloride Tablets.
Study Details
This study was a single-center, open, fixed-sequence, self-controlled trial design conducted in healthy subjects.
Key Dates
- Start date
- Dec 31, 2024
- Status verified
- Apr 2026
- Primary completion
- Jan 25, 2025
- Completion
- Jan 25, 2025
Study Design
- Enrollment
- 18 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment group
Primary Outcome Measure
Maximum plasma concentration (Cmax) [ Time Frame: 0 hour to 24 hours after the last dosing. ]
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Urinary Vitamin C Loss in Diabetic SubjectsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Personalized Environment and Genes StudyRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
- Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora PopulationsEnrolling By Invitation · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland